Pacific Biosciences of California, Inc.

NASDAQ:PACB

Medical - Devices

Healthcare
$1.83 +3.17%

+$0.04 today

Market cap
$571.39M
Beta
2.32
P/E (TTM)
-3.3
EPS (TTM)
-$0.42
52W Low $1.09High $2.73

Volume 15.30M

Average 6.06M

PACB Short-term Debt

Borrowings and the current portion of long-term debt due within one year.

Pacific Biosciences of California, Inc.NASDAQ: PACB

Short-term Debt · Q1 FY2026 · quarter ended Mar 2026

Short-term debt remains negative

Q1 FY2026 short-term debt was $277K, compared with $0 a year earlier. Over 3 fiscal years it compounded at -37.6% a year.

Context

  • Short-term debt amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Short-term debt increased in 1 of the last 3 fiscal years.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$277K— QoQ
Last fiscal yearDec 2025
$448K— YoY
Year agoMar 2025
$0— since
Short-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR-37.6%——
5-year CAGR——
10-year CAGR——

Short-term Debt history

USD · from the balance sheet

Latest · FY2025
448K USD
Year-over-year change
—
4-year CAGR
-27.3%

Short-term Debt vs competitors

How PACB compares with its peers on the latest reported figures

  • PACB's Mar 2026 short-term debt of $277K is the 2nd highest of the 3 companies compared; the peer median is $250M.
  • Short-term debt amounts to 0.0% of total assets for PACB, versus a peer median of 3.8%.
PACB Competitors Peer median
Short-term Debt for PACB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ILMNIllumina, Inc.Jun 2026$500M -13.5%-26.3%7.5%
PACBPacific Biosciences of California, Inc.Mar 2026$277K —-37.6%0.0%
QSIQuantum-Si incorporatedMar 2026$0 ——0.0%
Peer median (excluding PACB) $250M-13.5%-26.3%3.8%

Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents460.73M325.09M179.91M55.37M63.71M
Short-term Investments583.68M447.23M451.51M334.56M215.8M
Net Receivables24.24M18.79M36.62M27.52M35.45M
Inventory24.6M50.38M56.68M58.76M49.29M
Other Current Assets500K300K17.34M19.47M10.79M
Total Current Assets1.1B852.07M742.05M495.68M375.03M
Property, Plant & Equipment (Net)79.12M81.34M69.03M46.6M65.84M
Goodwill409.97M409.97M462.26M317.76M317.76M
Intangible Assets410.98M410.25M456.98M389.57M15.12M
Long-term Investments00001.53M
Tax Assets00000
Other Non-current Assets5.76M13.45M15.7M10.84M8.79M
Total Non-current Assets905.84M915.01M1B764.77M409.05M
Total Assets2.01B1.77B1.75B1.26B784.08M
Account Payables11M12.03M15.06M16.59M20.77M
Short-term Debt1.61M1.84M490K0448K
Tax Payables00000
Deferred Revenue10.98M30.5M16.34M13.86M0
Other Current Liabilities4.15M175.5M7.84M3.22M32.75M
Total Current Liabilities71.71M263.34M95.03M66.3M54.42M
Long-term Debt896.07M896.68M892.24M647.49M702.42M
Deferred Tax Liabilities(25.05M)0000
Deferred Revenue (Non-current)25.05M1.79M5.53M5.9M19.87M
Other Non-current Liabilities198.24M1.3M20.3M19.25M(55.01M)
Total Non-current Liabilities1.14B940.85M949.68M687.55M724.32M
Total Liabilities1.22B1.2B1.04B753.85M778.73M
Common Stock221K227K268K294K302K
Retained Earnings(1.22B)(1.53B)(1.84B)(2.15B)(2.7B)
Accumulated OCI(1.09M)(4.77M)219K422K457K
Other Stockholders Equity00000
Minority Interest00000
Total Equity790.99M562.9M701.3M506.59M5.35M
Total Debt955.36M948.48M933.93M672.43M759.46M
Net Debt494.63M623.39M754.02M617.06M695.76M

Pacific Biosciences of California, Inc.

NASDAQ:PACB

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.